JP2022513798A5 - - Google Patents

Info

Publication number
JP2022513798A5
JP2022513798A5 JP2021533535A JP2021533535A JP2022513798A5 JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5
Authority
JP
Japan
Prior art keywords
sequence
composition according
peptide
item
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513798A (ja
JP7664158B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066376 external-priority patent/WO2020124032A1/en
Publication of JP2022513798A publication Critical patent/JP2022513798A/ja
Publication of JP2022513798A5 publication Critical patent/JP2022513798A5/ja
Priority to JP2024214382A priority Critical patent/JP2025038018A/ja
Application granted granted Critical
Publication of JP7664158B2 publication Critical patent/JP7664158B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533535A 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド Active JP7664158B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024214382A JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779885P 2018-12-14 2018-12-14
US62/779,885 2018-12-14
US201962836520P 2019-04-19 2019-04-19
US62/836,520 2019-04-19
PCT/US2019/066376 WO2020124032A1 (en) 2018-12-14 2019-12-13 Transferrin receptor targeting peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024214382A Division JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Publications (3)

Publication Number Publication Date
JP2022513798A JP2022513798A (ja) 2022-02-09
JP2022513798A5 true JP2022513798A5 (cg-RX-API-DMAC7.html) 2022-12-20
JP7664158B2 JP7664158B2 (ja) 2025-04-17

Family

ID=71077078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533535A Active JP7664158B2 (ja) 2018-12-14 2019-12-13 トランスフェリン受容体標的ペプチド
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024214382A Pending JP2025038018A (ja) 2018-12-14 2024-12-09 トランスフェリン受容体標的ペプチド

Country Status (8)

Country Link
US (1) US20220048961A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893913B1 (cg-RX-API-DMAC7.html)
JP (2) JP7664158B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329758A (cg-RX-API-DMAC7.html)
AU (1) AU2019398467A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120466A1 (cg-RX-API-DMAC7.html)
IL (1) IL283839A (cg-RX-API-DMAC7.html)
WO (1) WO2020124032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP7231745B2 (ja) 2020-06-22 2023-03-01 中国科学院昆明▲動▼物研究所 抗SARS-CoV-2薬の調製における干渉ポリペプチドの応用
CN111647048B (zh) * 2020-06-22 2021-04-02 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
JP2022014707A (ja) * 2020-07-07 2022-01-20 東亞合成株式会社 キャリアペプチドフラグメントおよびその利用
EP4188422A4 (en) * 2020-07-30 2024-08-28 University of Washington Transferrin receptor binding proteins
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4298132A4 (en) * 2021-02-23 2025-03-12 Ichilov Tech Ltd. FUSION PROTEINS FOR THE TREATMENT OF CNS DISEASES
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
JPWO2023022234A1 (cg-RX-API-DMAC7.html) * 2021-08-19 2023-02-23
KR102934033B1 (ko) * 2021-10-01 2026-03-06 서울대학교산학협력단 혈액 뇌장벽 투과용 펩타이드 및 이의 용도
CN118139896A (zh) * 2021-10-15 2024-06-04 南通壹宸生物医药科技有限公司 一种双特异性结合分子
CN115160408B (zh) * 2022-06-29 2025-04-22 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981B (zh) * 2022-08-18 2025-05-23 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
TWI877887B (zh) * 2022-11-29 2025-03-21 法信諾生醫股份有限公司 轉運胜肽及其應用
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
KR20260021596A (ko) 2023-04-05 2026-02-13 아이오니스 파마수티컬즈, 인코포레이티드 Pln 발현을 감소시키는 화합물 및 방법
WO2024238304A2 (en) * 2023-05-12 2024-11-21 University Of Washington Improved transferrin receptor binding proteins
AU2024329222A1 (en) * 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025096245A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Design rules for endosomal escape
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用
CN120459270B (zh) * 2025-05-16 2026-06-09 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236499A1 (en) * 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20040157330A1 (en) * 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
WO2013123457A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013177062A2 (en) * 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
CA2967830A1 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CA3033082A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Similar Documents

Publication Publication Date Title
Dal Corso et al. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo
Thomas et al. Antibody–drug conjugates for cancer therapy
Nasiri et al. Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy
US10588938B2 (en) Receptor-based antagonists of the programmed cell death 1 (PD-1) pathway
ES2938186T3 (es) Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
Lancman et al. Bispecifics, trispecifics, and other novel immune treatments in myeloma
JP2023101813A (ja) 抗folr1免疫複合体を含む治療組み合わせ
EP2233156B1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
BR112015022585B1 (pt) Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
ES2872534T3 (es) Métodos para revertir la caquexia y prolongar la supervivencia que comprenden administrar un modulador de GDF15 y un agente anticanceroso
JP2021102648A (ja) 抗folr1免疫複合体投与計画
ES2875365T3 (es) Conjugados de fármaco de anticuerpos MET
CA2748291A1 (en) Cancer treatment
JP2019524713A5 (cg-RX-API-DMAC7.html)
CN108602890A (zh) 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
JP2020517658A5 (cg-RX-API-DMAC7.html)
JP7608336B2 (ja) 中枢神経系原発リンパ腫の併用治療
JP2024542021A (ja) ペイロードのin vivo標的化送達用のテトラジンコンジュゲート
JP2020527556A5 (cg-RX-API-DMAC7.html)
Wu Enhancement of immunotoxin activity using chemical and biological reagents
WO2023081809A1 (en) Trans-cyclooctene-modified bispecific antibodies
JP6782932B2 (ja) Npr−aアゴニストの新規用途
EP4472741A1 (en) Combination therapy comprising anti-ccr9 antibody and vincristine for cancer
Koli et al. Lung cancer receptors and targeting strategies